Development of a hypoxia-responsive vector for tumor-specific gene therapy

Area of Science:

• Molecular Biology
• Gene Therapy
• Oncology

Background:

• Hypoxia, or low oxygen, is a hallmark of solid tumors.
• Gene therapy vectors typically lack tumor-specific activation mechanisms.
• Vascular endothelial growth factor (VEGF) expression is upregulated by hypoxia.

Purpose of the Study:

• To develop novel gene therapy vectors with hypoxia-inducible expression for selective tumor targeting.
• To optimize vector design by evaluating hypoxia-responsive elements (HREs) and promoter combinations.
• To assess the impact of VEGF 3'-untranslated region (UTR) on mRNA stability and gene expression under hypoxia.

Main Methods:

• Constructing gene therapy vectors containing multiple HREs from the human VEGF 5'-UTR.
• Testing various combinations of HREs and promoters for hypoxia-induced transcriptional activity.
• Evaluating the effect of the VEGF 3'-UTR on mRNA stability using luciferase reporter assays under hypoxic and normoxic conditions.

Main Results:

• Five copies of VEGF-derived HREs demonstrated strong transcriptional activation under hypoxic conditions.
• The combination of 5HRE and a CMV minimal promoter achieved over 500-fold hypoxia-inducible expression.
• Inclusion of the VEGF 3'-UTR led to decreased gene expression due to mRNA destabilization by AU-rich elements (AREs).

Conclusions:

• A novel gene therapy vector utilizing 5HRE and a CMV minimal promoter exhibits robust, tumor-specific hypoxia-inducible gene expression.
• This vector design offers a promising strategy for targeted gene therapy in solid tumors.
• The VEGF 3'-UTR does not enhance, and may hinder, hypoxia-inducible gene expression due to mRNA destabilization.